Kilitch Drugs India Bonus Share Approval and Capital Doubling

The Board of Directors of Kilitch Drugs (India) Ltd. met on March 25, 2026, to approve a significant corporate action: a 1:1 bonus equity share issue. This means for every equity share an investor holds, they will receive one additional bonus share free of cost.

The company plans to issue 1,74,80,782 bonus shares, each with a face value of Rs. 10. This issuance will effectively double the company's pre-bonus paid-up share capital from Rs. 17.48 crore to Rs. 34.96 crore. The record date for determining eligible shareholders for this bonus issue has been set as March 24, 2026.

Why the Bonus Issue Matters

Bonus issues are a common method for companies to reward shareholders by capitalizing their retained earnings. The increase in the number of shares in circulation can enhance stock liquidity, making it more accessible to a wider range of investors. While shareholders receive more shares without additional investment, their overall ownership percentage remains unchanged, and the stock's per-share price typically adjusts downwards on the ex-bonus date.

Company Background and Recent Performance

Kilitch Drugs (India) Ltd. is a pharmaceutical manufacturer with a diverse product portfolio, including injectables, oral formulations, and medical devices. The company has established a global presence, with notable operations in Ethiopia. Recent financial reports show strong performance in Q4 FY25, with consolidated net revenue increasing by 178% and a net profit of ₹10 crore. For the full fiscal year FY25, the company reported ₹181 crore in revenue and ₹31 crore in net profit.

However, the company's financial trajectory has shown some volatility. Standalone revenue declined in Q4 FY24. More recently, Q1 FY26 results indicated a decrease in profit after tax (PAT) and net sales, coupled with rising interest expenses. Kilitch Drugs is currently undertaking a capital expenditure of ₹100-125 crore for capacity expansion at its Khopoli, Maharashtra facility, which is slated for completion in FY25-26.

Key Changes for Shareholders and Capital

Following the board's approval, shareholders will receive one bonus share for every share they hold. This will lead to an increase in the total number of outstanding equity shares. Consequently, Kilitch Drugs' total paid-up equity share capital will double from approximately ₹17.48 crore to ₹34.96 crore. The face value per share will remain Rs. 10, and the newly issued bonus shares will rank pari-passu with existing shares.

Potential Risks to Consider

Investors should be aware of potential operational risks within the group. In April 2024, a related entity, Kilitch Healthcare India, received a warning letter from the USFDA concerning manufacturing lapses and insanitary conditions at its Navi-Mumbai plant. This led to a suspension of US market production and product recalls. While this issue pertains to a specific entity, it may indicate broader operational challenges. Furthermore, recent financial performance has been mixed, with some quarters showing revenue and profit pressures that warrant monitoring.

Competitive Landscape

Kilitch Drugs operates within the highly competitive Indian pharmaceutical market. Its key peers include established major players such as Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., and Dr Reddy's Laboratories Ltd., many of whom possess diverse portfolios and significant market shares.

What to Watch For

Key factors to monitor going forward include the market's reaction to the bonus issue announcement and subsequent trading activity. Investors will also be keen to see the company's ability to sustain its Q4 FY25 financial performance in upcoming quarters. Progress on the ₹100-125 crore capacity expansion project in Khopoli is another critical area. Any further updates or resolutions regarding the USFDA warning letter issued to Kilitch Healthcare India will be important, as will the company's dividend distribution policy following the increase in its share capital.